Litigation Details for Natera, Inc. v. NeoGenomics Laboratories, Inc. (Fed. Cir. 2024)
✉ Email this page to a colleague
Natera, Inc. v. NeoGenomics Laboratories, Inc. (Fed. Cir. 2024)
| Docket | ⤷ Start Trial | Date Filed | 2024-01-04 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2024-07-12 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 8,389,578 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Natera, Inc. v. NeoGenomics Laboratories, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for Natera, Inc. v. NeoGenomics Laboratories, Inc. (Fed. Cir. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-01-04 | External link to document | |||
| 2024-01-04 | 20 | / 1998 Bogart 8,389,578 B2 3/2013 Went et al. 5,753,467 … method patents. Patent No. 11,519,035 issued on December 6, 2022, Doc. 1-2 at 2, and Patent No. 11,530,454…the ’454 patent in Natera, Inc. v. Inivata, Inc., 1:22-cv-01609 (D. Del.). The same patent is also currently… assessing Natera’s patent, both on invalidity and infringement. Natera’s patent, with an alleged 2011…Despite that narrow patent description, the much-later-drafted claims of the ’035 patent generically recite | External link to document | |
| 2024-01-04 | 42 | / 1998 Bogart 8,389,578 B2 Went et al. …1998 Mascarenhas 8,389,578 B2 3/2013 Went et al. 5,854,033 … in the art (see, e.g., U.S. Pat. Nos. 8,389,578 and 8,389,557, diagnosed with cancer or an increased… method patents. Patent No. 11,519,035 issued on December 6, 2022, Doc. 1-2 at 2, and Patent No. 11,530,454…Natera’s U.S. Patent Nos. 11,530,454 (the “’454 Patent”) and 11,519,035 (the “’035 Patent”) (collectively | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
